z-logo
Premium
Retracted: LncRNA XIST functions as a molecular sponge of miR‐194‐5p to regulate MAPK1 expression in hepatocellular carcinoma cell
Author(s) -
Kong Qinglei,
Zhang Shaoquan,
Liang Caiqian,
Zhang Ying,
Kong Qingcong,
Chen Shuxian,
Qin Jie,
Jin Yi
Publication year - 2018
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.26540
Subject(s) - xist , long non coding rna , gene silencing , biology , cancer research , downregulation and upregulation , microrna , carcinogenesis , cell growth , hepatocellular carcinoma , cancer , x inactivation , genetics , gene , x chromosome
Abstract Increasing evidence highlights the important role of XIST, a long non‐coding RNA (lncRNA), in the regulation of multiple cancers. However, the underlying mechanism of XIST in human hepatocellular carcinoma (HCC) still remains to be explored. Herein, intended to investigate the functional role of XIST in HCC initiation and progression. We first detected that XIST was significantly upregulated in HCC tissues and associated with tumor size and vascular invasion. Gain‐ and loss‐of‐function of XIST further presented that XIST promoted the progression of HCC cells, including proliferation, migration, and invasion. Moreover, silencing of XIST could inhibit tumor growth in vivo. We also found that XIST could target miR‐194‐5p and thus decrease miR‐194‐5p expression. Besides that, restoring XIST could reverse the inhibitory effect of miR‐194‐5p on the proliferation and invasion of HCC cells. We further elucidated such rescue role might through derepressing MAPK1 expression, the target of miR‐194‐5p. In brief, the above results elucidate the important role of XIST in HCC tumorigenesis, suggesting that XIST might be a candidate prognostic biomarker and a novel therapeutic target for treating HCC.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here